IP Library Granted Patent US 10,899,729
Granted Patent B2
US 10,899,729 · App. 16/314,555 · Granted Jan 26, 2021

Method for producing bicyclic compound

Inventors: Hideki Moriguchi (Osaka, JP); Yusuke Tanaka (Osaka, JP); Tatsunori Ino (Osaka, JP); Tohru Kambe (Osaka, JP); Taihei Nishiyama (Osaka, JP); Shinichiro Tsujiyama (Osaka, JP); Yohei Ueda (Osaka, JP)
Assignee: ONO PHARMACEUTICAL CO.. LTD.
C07D313/06C07C69/65C07C69/75C07D307/937
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,899,729
App. No.
16/314,555
Granted
Jan 26, 2021
Kind
B2
Abstract

A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.

Claims (58)

1. A method for producing a compound represented by formula (G) or a salt thereof:

wherein, R 1 represents a C1-6 alkyl group optionally substituted with a hydroxyl group or a C1-4 alkoxy group, Z represents (1) —(CH 2 ) m —, (2) —(CH 2 ) n —CH═CH—, or (3) —(CH 2 ) p -A-CH 2 —, A represents an oxygen atom, or a sulfur atom, m represents an integer of 1 to 6, n represents an integer of 1 to 4, and p represents an integer of 1 to 4, and T 1 represents (1) a p-phenybenzoyl group, (2) a methyl group, (3) a trityl group, (4) a methoxymethyl group, (5) a 1-ethoxyethyl group, (6) a methoxyethoxymethyl group, (7) a benzyloxymethyl group, (8) a trimethylsilyl group, (9) a triethylsilyl group, (10) a t-butyldimethylsilyl group, (11) a t-butyldiphenylsilyl group, (12) a triisopropylsilyl group, (13) a benzyl group, (14) a p-methoxybenzyl group, (15) an acetyl group, (16) a pivaloyl group, (17) a benzoyl group, (18) an allyloxycarbonyl group, (19) a 2,2,2-trichloroethoxycarbonyl group, (20) a t-butoxycarbonyl group, (21) an allyl group, or (22) a tosyl group,

the method comprising the following steps (i) to (vi):

step (i): subjecting a compound represented by formula (A):

wherein, T 2 represents a benzyl group, and other symbols represent the same meanings as those described above,

to a reduction reaction to produce a compound represented by formula (B):

wherein, all symbols represent the same meanings as those described above,

or a salt thereof;

step (ii): subjecting the compound represented by formula (B) obtained in the step (i) or a salt thereof to a reaction in an organic solvent, in the presence of a base using a Wittig reagent to produce a compound represented by formula (C):

wherein, all symbols represent the same meanings as those described above,

or a salt thereof;

step (iii): subjecting the compound represented by the formula (C) obtained in the step (ii) or a salt thereof and a compound represented by formula (a):

wherein, X represents a halogen atom, a tosyloxy (TsO) group, or a mesyloxy (MsO) group, and other symbols represent the same meanings as those described above,

to an alkylation reaction to produce a compound represented by formula (D):

wherein, all symbols represent the same meanings as those described above;

step (iv): subjecting the compound represented by the formula (D) obtained in the step (iii) to a metathesis reaction to produce a compound represented by formula (E):

wherein, all symbols represent the same meanings as those described above;

step (v): subjecting the compound represented by the formula (E) obtained in the step (iv) to an asymmetric reduction reaction to produce a compound represented by formula (F):

wherein, all symbols represent the same meanings as those described above; and

step (vi): subjecting the compound represented by the formula (F) obtained in the step (v) to a deprotection reaction to produce the compound represented by the formula (G) or a salt thereof.

2. A method for producing a compound represented by formula (K):

wherein, Y represents —CH 2 —, —O— or —S—, represents a C3-10 carbocycle or a 3- to 10-membered heterocycle optionally substituted with 1 to 5 substituents selected from the group consisting of (1) a halogen atom, (2) CF 3 , (3) OCF 3 , (4) a C1-4 alkoxy group, (5) a C1-4 alkyl group, (6) a hydroxyl group, and (7) a nitrile group, R 1 represents a C1-6 alkyl group optionally substituted with a hydroxyl group or a C1-4 alkoxy group, Z represents (1) —(CH 2 ) m —, (2) —(CH 2 ) n —CH═CH—, or (3) —(CH 2 ) p -A-CH 2 —, A represents an oxygen atom, or a sulfur atom, m represents an integer of 1 to 6, n represents an integer of 1 to 4, and p represents an integer of 1 to 4,

the method comprising:

producing a compound represented by formula (G) or a salt thereof from a compound represented by formula (A) according to steps (i) to (vi):

wherein, T 1 represents (1) a p-phenybenzoyl group, (2) a methyl group, (3) a trityl group, (4) a methoxymethyl group, (5) a 1-ethoxyethyl group, (6) a methoxyethoxymethyl group, (7) a benzyloxymethyl group, (8) a trimethylsilyl group, (9) a triethylsilyl group, (10) a t-butyldimethylsilyl group, (11) a t-butyldiphenylsilyl group, (12) a triisopropylsilyl group, (13) a benzyl group, (14) a p-methoxybenzyl group, (15) an acetyl group, (16) a pivaloyl group, (17) a benzoyl group, (18) an allyloxycarbonyl group, (19) a 2,2,2-trichloroethoxycarbonyl group, (20) a t-butoxycarbonyl group, (21) an allyl group, or (22) a tosyl group, and other symbols represent the same meanings as those described above,

step (i): subjecting a compound represented by formula (A):

wherein, T 2 represents a benzyl group, and other symbols represent the same meanings as those described above,

to a reduction reaction to produce a compound represented by formula (B):

wherein, all symbols represent the same meanings as those described above,

or a salt thereof;

step (ii): subjecting the compound represented by formula (B) obtained in the step (i) or a salt thereof to a reaction in an organic solvent, in the presence of a base using a Wittig reagent to produce a compound represented by formula (C):

wherein, all symbols represent the same meanings as those described above,

or a salt thereof;

step (iii): subjecting the compound represented by the formula (C) obtained in the step (ii) or a salt thereof and a compound represented by formula (a):

wherein, X represents a halogen atom, a tosyloxy (Ts0) group, or a mesyloxy (Ms0) group, and other symbols represent the same meanings as those described above,

to an alkylation reaction to produce a compound represented by formula (D):

wherein, all symbols represent the same meanings as those described above;

step (iv): subjecting the compound represented by the formula (D) obtained in the step (iii) to a metathesis reaction to produce a compound represented by formula (E):

wherein, all symbols represent the same meanings as those described above;

step (v): subjecting the compound represented by the formula (E) obtained in the step (iv) to an asymmetric reduction reaction to produce a compound represented by formula (F):

wherein, all symbols represent the same meanings as those described above; and

step (vi): subjecting the compound represented by the formula (F) obtained in the step (v) to a deprotection reaction to produce the compound represented by the formula (G) or a salt thereof;

producing a compound represented by formula (I) or a salt thereof from the compound represented by the formula (G) or a salt thereof according to steps (vii) to (viii):

wherein, all symbols represent the same meanings as those described above,

step (vii): subjecting a compound represented by formula (G):

wherein, all symbols represent the same meanings as those described above, or a salt thereof to an oxidation reaction to produce a compound represented by formula (H):

wherein, all symbols represent the same meanings as those described above; and

step (viii): subjecting the compound represented by the formula (H) obtained in the step (vii) and a compound represented by formula (b):

wherein, R 101 represents a C1-6 alkyl group, and other symbols represent the same meanings as those described above,

to a reaction in an organic solvent, in water, or in a mixed solution thereof, in the presence of a base, in the presence or absence of an additive to produce the compound represented by the formula (I) or a salt thereof; and

producing the compound represented by the formula (K) according to steps (ix) to (x):

step (ix): subjecting a compound represented by formula (I):

wherein, all symbols represent the same meanings as those described above, or a salt thereof, to an asymmetric reduction reaction to produce a compound represented by formula (J) or a salt thereof:

wherein all symbols represent the same meanings as those described above; and

step (x): subjecting the compound represented by the formula (J) or a salt thereof to a deprotection reaction to produce the compound represented by the formula (K).

3. The method according to claim 1 , wherein T 1 is a p-phenybenzoyl group.

4. The method according to claim 2 , wherein the compound represented by the formula (K) is 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate.

5. The method according to claim 2 , wherein T 1 is a p-phenybenzoyl group.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: FUJIFILM WAKO PURE CHEMICAL CORPORATION
To: ONO PHARMACEUTICAL CO., LTD.
Reel/Frame 048846/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: TSUJIYAMA, SHINICHIRO; UEDA, YOHEI
To: FUJIFILM WAKO PURE CHEMICAL CORPORATION
Reel/Frame 048809/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: MORIGUCHI, HIDEKI; TANAKA, YUSUKE; INO, TATSUNORI; KAMBE, TOHRU; NISHIYAMA, TAIHEI
To: ONO PHARMACEUTICAL CO., LTD.
Reel/Frame 048814/0620 →
Priority Claims (1)
JP 2016-129877 · Jun 30, 2016 · national
Continuity (1)
Related Publication 20190315705A1 · Oct 17, 2019
Cited By (2)
US 12,201,603 US 12,232,744